MGMT and glioblastoma: In the CheckMate⁃498 trial (NCT02617589), newly diagnosed GBM patients with unmethylated O6-methylguanine-DNA methytransferase (MGMT) promoter who received nivolumab plus radiotherapy did not benefit from this treatment compared with radiotherapy plus temozolomide (TMZ) as measured by OS (86).